Ignite Creation Date:
2024-05-05 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00791700
Status:
UNKNOWN
Last Update Posted:
2020-04-28
First Post:
2008-11-12
Brief Title:
An Open Label Pharmacokinetic Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected CCR5 -Tropic Children
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
AN OPEN-LABEL MULTICENTER MULTIPLE-DOSE PHARMACOKINETIC SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2 - 18 YEARS OF AGE
Status:
UNKNOWN
Status Verified Date:
2020-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine the pharmacokinetic properties what the body does to maraviroc and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents This study will also determine whether maraviroc is safe to use in children and adolescents
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-006873-33 | EUDRACT_NUMBER | None | None |